Exposure-Response Relationships of Antibody Drug Conjugates in Solid Tumours.

Clin Pharmacokinet · 2026 · PMC13183693 · PMID 41920510

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, the enfortumab-vedotin exposure-efficacy analysis showed a trend toward a better response at higher enfortumab-vedotin exposure quartiles (55–65% ORR for the upper three exposure quartiles vs 32% ORR for lowest exposure quartile).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.